The goal of the National Institute of Neurological Disorders and Stroke (NINDS)-funded Neuro-QoL project was to develop a core set of universally applicable HRQL questions supplemented with diseasespecific questions for patients with chronic neurological conditions. The project underwent multiple phases leading up to the final clinical validation of the Neuro-QoL item banks and associated short forms (SFs), which are brief, fixed-length forms of six to 10 items each. The adult conditions included in NeuroQoL were amyotrophic lateral sclerosis (ALS), adult epilepsy, MS, Parkinson's disease, and stroke. Two pediatric conditions were also included: pediatric epilepsy and muscular dystrophy. The developers ensured clinical and psychometric validity of these tools by identifying the needs of the clinical research community, 6, 7 ensuring clinical and patient-driven evidence of importance and relevance of the selected quality of life (QoL) domains, and an expert-based consensus selection of the priority conditions. 8 Input from experts, caregivers, and patients determined the QoL domains included in the Neuro-QoL. 9 Item banks for each of the 13 domains were constructed and calibrated using IRT in a sample of adults and children from the general population (GP) and clinical sample (CS) of those suffering from neurological conditions as previously described [9] [10] [11] with scoring and interpretation details available online via Neuro-QoL. 12 In this paper we report the multi-site validation of the Neuro-QoL SFs with a clinical sample of adult MS patients.
Materials and methods

Participants and procedures
We compared cross-sectional and longitudinal data from the Neuro-QoL SFs, MS-specific and generic legacy measures, and the Patient-Reported Outcomes Measurement Information System (PROMIS) global health scale. Patients were recruited as part of a large multicenter study to validate Neuro-QoL measures across five adult and two pediatric neurological diseases. The five MS sites (Cleveland Clinic, Dartmouth-Hitchcock Medical Center, NorthShore University Health System, University of Chicago Hospital, and the University of Texas Health Science Center at San Antonio) all had institutional review board (IRB) approvals. Study inclusion criteria for adults were: age 18 or older, English-speaking, community resident, and having sufficient cognitive ability to complete the informed consent process for each participating site. MS-specific inclusion criteria were clinician-confirmed diagnosis of MS. The participants included were a convenience sample of consecutive clinic attendees.
Data collection and management
Data were collected at three time points: Baseline, Day-7 and Month-6. Baseline and Month-6 data were collected at the clinical sites and Day-7 data were collected by phone. There was a five-to nineday window for the test-retest assessment (Day-7) and a five-to seven-month window for the responsiveness assessment (Month-6). Baseline and Month-6 evaluations included the Neuro-QoL instruments, concurrent validity measures, and sociodemographic and clinical data forms that were self-administered by computer or conducted by study personnel. Clinician ratings and chart reviews were also conducted as part of these two visits. The 30-minute Day-7 visit was conducted to assess testretest performance of the Neuro-QoL instruments administered to participants over the phone by study personnel. All data were submitted to, and managed by, the coordinating center at Northwestern University.
Measures
Neuro-QoL SFs were validated in relation to generic and MS-specific measures of physical, mental and social functional status, and disease severity. These data were obtained by participant self-rated and clinical assessments (Table 1) .
Neuro-QoL. The 13 Neuro-QoL SFs ( Figure 1 ) were self-administered at baseline and Month-6 and administered at Day-7 via phone. T scores were calculated with a T = 50 indicating an average range of function compared to a reference population with a standard deviation (SD) of 10. GP T scores were the reference values for Neuro-QoL Positive Affect and WellBeing, Applied Cognition General Concerns, Applied Cognition-Executive Function, Lower Extremity (Mobility), Upper Extremity (Fine Motor, ADL), Ability to Participate in Social Roles and Activities, Satisfaction with Social Roles and Activities, Depression and Anxiety. CS T scores were the reference values for Stigma, Fatigue, Sleep Disturbance, and Emotional and Behavioral Dyscontrol. 13 rates functional impairment and diagnosis-independent breakdown of activity level across patients. 14 tests information processing speed, visual acuity, and figural memory. The oral version was administered.
General function measures to assess convergent validity (baseline). Karnofsky Performance Status Scale (KPS)
Cognitive Function. Symbol Digit Modalities Test (SDMT)
Generic HRQL. EQ-5D 15, 16 is a five-item, three response levels per item self-reported health status measure that provides a simple, generic HRQL preference measure for economic evaluation. 17 items include global ratings of the five primary PROMIS domains (physical function, fatigue, pain, emotional distress, and social health) and general health perceptions that cut across domains. It can be scored into a Global Physical Health component and Global Mental Health component.
PROMIS 10-Item Global Health Scale (GHS)
Global HRQL Question (GHQ): 18 A single item from the Functional Assessment of Chronic Illness Therapy (FACIT), "I am content with the quality of my life right now," was used as a global measure of QOL and assessment of convergent validity. It has five response options, ranging from "not at all" to "very much."
General function measures to assess responsiveness. Global Rating of Change (GRC) 19 is an assessment of patients' subjective evaluation of the amount of change they experienced over the six-month period of the study. We have previously simplified the original 15-level response option to a seven-level option, now ranging from −3 = "very much worse" to +3 = "very much better." 20 22 is an MS-specific measure to assess the convergent validity in this population including 44 items summarized into six subscales: mobility, symptoms, emotional well-being (depression), general contentment, thinking/fatigue, and family/social well-being.
Statistical analysis
Descriptive statistics were calculated for the NeuroQoL, external validation measures, and socio-demographic and clinical variables at the baseline assessment and follow-up visits. When comparing MS patients' Neuro-QoL T scores with the GP and CS reference groups, score difference less than 0.5 SD units (i.e. five points, range 45-55) was considered to be within the range of the reference groups' average.
Reliability. Internal consistency was calculated for
Neuro-QoL SF baseline scores using Cronbach's alpha coefficient with coefficient scores of 0.70 or higher considered acceptable. Test-retest reliability of NeuroQoL SFs at baseline and Day-7 was assessed with intraclass correlation coefficients (ICC) and corresponding 95% confidence intervals (CIs), with coefficient scores of 0.70 or higher considered acceptable.
Validity. Concurrent validity was assessed at baseline by calculating the Spearman rho correlation coefficients between Neuro-QoL SF scores and the generic and disease-specific legacy measures. Interpretation guidelines for these correlations were: <0.30 = nominal; 0.30-0.49 = small; 0.5-0.69 = moderate; ⩾0.70 = large. The strength of these correlations was hypothesized a priori to the analysis and results are based on those predictions, with correlations >0.50 considered acceptable. Known groups validity was assessed at baseline using analysis of variance comparing baseline mean Neuro-QoL SF scores between MS patients grouped by MS severity using the MSFC and selfreported GHQ.
Responsiveness. Neuro-QoL sensitivity to change was conducted by evaluating general linear models using each patient's change score between Month-6 and baseline relative to change in the generic GRC. A correlation of ⩾ 0.30 was set as the criterion for responsive with p ⩽ 0.05 considered moderately significant and p = 0.001 highly significant.
No imputation of missing data was calculated for patients who failed to participate at the sensitivity to change assessment; however, we prospectively monitored the reasons for missing data (e.g. refusal, disease progression, death) and compared characteristics of patients who did and did not participate.
Results
Baseline demographics
A total of 161 MS participants completed the baseline assessment with 132 also completing the Month-6 assessments. Baseline demographics indicated that participants were predominantly female (86%), white (88%), and non-Hispanic (93%). Their average age was 49.8 years (SD = 10.5), 58.4 % were married and 90% had some college education or degree. Thirtyseven percent were on disability and 34% were fully employed. MSFC scores ranged from −2.90 to 1.7, with a mean (M) of 0.0 (SD = 0.69). The most common disease courses were relapsing-remitting (62.9%) and secondary progressive (28.9%). No systematic differences were found between participants who did or did not complete all assessments or in these scores across the five study sites (data not shown). Table 2) .
Correlations for Neuro-QoL SF T scores with generic measures
The KPS correlated highly with Lower Extremity and moderately with Upper Extremity, Satisfaction with Roles and Activities, and Stigma (Table 3) . Two correlations for Depression and Fatigue did not meet the criterion (r > 0.50). The EQ-5D moderately correlated with six of the 13 Neuro-QoL measures and demonstrated low correlations with the remaining seven. The Global QOL question met the high correlation criterion for Ability to Participate in Social Roles and Positive Affect and Well-Being, and correlated moderately with the other scales, except for the Upper and Lower Extremity Functioning and Applied Cognition.
Correlations for Neuro-QoL SF T scores with MSspecific measures
Six of the Neuro-QoL measures strongly correlated with the FAMS total score and the remaining seven only moderately correlated, with the highest being Satisfaction with Social Roles (r = 0.830) and lowest being Upper Extremity (Fine Motor; r = 0.578) ( Table 4 (a)).
Five Neuro-QoL measures demonstrated strong correlations with the FAMS subscales, the strongest being between FAMS General Contentment and Neuro-QoL Positive Affect and Well-Being (r = 0.862) and between FAMS Mobility and Neuro-QoL Lower Extremity (r = 0.862) with the remaining subscales demonstrating moderate correlations (Table 4 (b)).
The MSFC total moderately correlated with Lower Extremity (r = 0.546) and Upper Extremity (r = −0.591) but not with cognition or depression NeuroQoL measures. The MSFC T-25-FW strongly correlated with Mobility (r = 0.81), the MSFC 9-HPT moderately correlated with Upper Extremity (r = 0.631) and the MSFC-SDMT had only low correlations with the Neuro-QoL scales. Table 5 ).
Responsiveness to change
Each of the Neuro-QoL SFs responsiveness from baseline to Month-6 was based on the responses to the six GRC scores ( The MSFC is a clinical assessment of MS disability that includes a total score and a score for each of its components; as expected the total MSFC score showed moderate correlations with the Lower Extremity and Upper Extremity but the overall MSTP did not correlate with the Cognitive, Social or Emotional domains. The lack of correlation between the SDMT and the two Neuro-QoL cognition measures is consistent with reports of poor correlation between self-reported cognition and neuropsychological tests. [23] [24] [25] Since the only significant correlation the MSFC had was with the Neuro-QoL Lower and Upper Extremity scales, it is not surprising that only those two measures demonstrated known groups discrimination. In contrast, when grouped by the GHQ, all of the domains showed between-group discrimination.
This sample of MS patients showed very limited change in their status over the six-month period of this observational study. This is expected given that most studies of MS disease-modifying therapies require a 24-month period to distinguish between treatment arms. It is not surprising that there was limited responsiveness to change in the Neuro-QoL measures; there were similarly limited changes in FAMS scores over the same study period (data not shown).
Individuals with MS included in this sample experienced a rather limited level of disability as they needed to be able to have walking and hand function that allowed them to complete the MSFC. While a T score is interpreted relative to a reference population, improved understanding of the "meaning" of a score in the context of individuals living with a given disease will lend clinical meaningfulness to these measures. Work is underway to improve such interpretation guidelines. 26, 27 Conclusions These data provide initial validation for the NeuroQoL SF measures in a sample of people with MS. The measures demonstrate strong internal consistency and test-retest reliability. Given their focus on QOL in neurological conditions, their stronger correlation with other disease-specific PROs compared to generic PROs, and stronger correlations with PROs than with clinical measures of MS severity is expected. The Neuro-QoL assesses several domains of well-being not typically assessed using traditional MS-specific PROs. Those additional domains include Positive Affect and Well-Being and Emotional and Behavioral Dyscontrol. The relevance of Stigma as a component of QOL clearly emerged from these data. The availability of one PRO measure that assesses physical, cognitive, and emotional domains of well-being and has been evaluated using a unified validation approach in five adult and two pediatric neurological conditions represents a major advancement in the ability to assess the impact of different interventions within one disease group and across individuals living with several neurological diseases. We believe Neuro-QoL provides an excellent opportunity for researchers and clinicians alike to explore aspects of MS patients' experiences that have not been previously studied and advances opportunities to study the impact of different diseases across neurological conditions.
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